Insmed (NASDAQ: INSM) has significantly outperformed the broader market over the past 15 years, delivering an average annual return of 24.7%. This performance represents a 11.06% annualized outperformance relative to the market benchmark.

An initial investment of $1,000 in Insmed stock made 15 years ago would be valued at $27,361.95 today. This valuation is based on a current share price of $116.95.

Market capitalization and performance metrics

The company currently holds a market capitalization of $25.54 billion. The long-term compounding effect illustrates how sustained growth impacts investor wealth over extended periods.

Compounding impact on returns

The data highlights the substantial difference compounded returns can make on cash growth over a 15-year horizon. The disparity between the initial principal and the final value underscores the power of long-term holding in high-growth equities.

Insmed Incorporated (NASDAQ: INSM) announced that the U.S. Food and Drug Administration has accepted its supplemental new drug application for Arikayce. The agency granted Priority Review for the treatment of Mycobacterium avium complex (MAC) lung disease.

The FDA set a target action date of January 28, 2027, under the Prescription Drug User Fee Act. This acceptance marks a key regulatory milestone for the biopharmaceutical company's pipeline.

Regulatory Context

The FDA grants Priority Review to applications that offer significant improvements in safety or effectiveness for serious conditions. Arikayce received accelerated approval in 2018 for refractory MAC lung disease. It was the first product approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.

This pathway was enacted under the 21st Century Cures Act to advance therapies for serious infections in patients with unmet needs.

Clinical Data Support

The supplemental application relies on results from the Phase 3b ENCORE study. This pivotal trial fulfilled the post-marketing requirement linked to the drug's initial accelerated approval.

The study showed that Arikayce plus multidrug therapy improved respiratory symptoms and culture conversion in adults compared to multidrug therapy alone.

Future Outlook

Martina Flammer, Chief Medical Officer, stated that full approval could allow earlier treatment for patients newly diagnosed or facing recurrent infections. She emphasized that MAC lung disease is progressive, causing greater tissue damage over time.

Insmed plans to review the ENCORE data with the Pharmaceuticals and Medical Devices Agency in Japan during the fourth quarter of 2026. This step aims to support potential label expansion in the Japanese market.